After striking a Most Favored Nation deal with the White House in January, Johnson & Johnson will now offer Xarelto at 68% ...

Trained biostatisticians play a central role in clinical science and public health. Brown’s online master’s in biostatistics ...

As cell and gene therapy leaders gathered in Maryland to discuss accelerating clinical trials in children, one “cutting edge” ...

Of the 17 companies that were implored by the White House last July to apply Most Favored Nation pricing to their drugs, ...

Pfizer’s decision to cut its early-stage cancer asset was due to “strategic business reasons” and not driven by safety or ...

Daiichi Sankyo’s full-year report was originally scheduled for April 27 but has now been pushed back to May 11. That same day ...

While the FDA did not announce the recipient names of the Commissioner’s National Priority Vouchers, the agency’s ...

In the U.S., Moderna withdrew its approval application for the combination vaccine in May last year and the timeline for ...

The Durham plant will manufacture immunology, neuroscience and oncology drugs once AbbVie finishes construction in 2028.

A triplet regimen comprising Merck’s Welireg and PD-1 blockbuster Keytruda and Eisai’s Lenvima flopped in a Phase 3 renal ...

Chief Scientific Officer Pedro Beltran will succeed Eli Wallace as CEO of BridgeBio Oncology Therapeutics, as the board eyes ...

At Sarepta Therapeutics, we’ve seen it all. Here are the questions I believe we should be asking to move forward in Duchenne ...